<?xml version="1.0" encoding="UTF-8"?>
<p>In contrast, EA submissions are for products used under an IND or a protocol (treatment plan), or submitted as a protocol amendment to an existing or new IND. The EA categories cover use under either an individual patient IND or protocol, individual emergency EA use, or EA for an intermediate‐size population or for widespread use (large populations). Other US regulatory programmes for biologicals and drugs to treat serious or life‐threatening conditions include fast‐track designation, breakthrough therapy designation, accelerated approval pathway and priority review designation.</p>
